Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Market Chatter: Johnson & Johnson Reportedly Asked Other COVID-19 Vaccine Producers to Jointly Study Clotting Risks

04/16/2021 | 09:08am EDT


© MT Newswires 2021
All news about JOHNSON & JOHNSON
05/07Correction to Impact of U.S. Support for Patent Waiver on Vaccine Makers Arti..
DJ
05/07AstraZeneca Weighs Seeking Full U.S. Approval for Covid Shot, Skipping Emerge..
DJ
05/07AstraZeneca Weighs Seeking Full U.S. Approval for Covid Shot, Skipping Emerge..
DJ
05/07MARKET CHATTER : WHO's Director General Calls for Countries to Support Waiving C..
MT
05/07JOHNSON & JOHNSON  : Alberta truckers delivering in Montana can get COVID-19 vac..
AQ
05/07U.S. Support for Patent Waiver Unlikely to Cost Covid-19 Vaccine Makers in Sh..
DJ
05/07WHO Endorses China's Covid-19 Vaccine Sinopharm -- 4th Update
DJ
05/07JOHNSON & JOHNSON  : Health Care Workers Urged to Vaccinate in Sisonke Protocol
AQ
05/07Pfizer, BioNTech Apply for Full US Food and Drug Administration Approval of C..
MT
05/07JOHNSON & JOHNSON  : to Participate in Goldman Sachs 42nd Annual Global Healthca..
PU
More news
Financials (USD)
Sales 2021 92 843 M - -
Net income 2021 22 226 M - -
Net Debt 2021 1 328 M - -
P/E ratio 2021 20,3x
Yield 2021 2,49%
Capitalization 444 B 444 B -
EV / Sales 2021 4,79x
EV / Sales 2022 4,46x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 183,32 $
Last Close Price 168,50 $
Spread / Highest target 21,1%
Spread / Average Target 8,79%
Spread / Lowest Target -6,23%
EPS Revisions
Managers and Directors
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON7.07%443 727
ROCHE HOLDING AG-1.88%289 958
PFIZER, INC.6.47%220 784
ABBVIE INC.8.03%204 279
MERCK & CO., INC.-4.14%198 539
NOVARTIS AG-4.97%197 775